Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Abstract

Axillary lymph node assessment is one of the important indicators in the clinical pathological staging of breast cancer. Studies have shown that sentinel lymph node biopsy (SLNB) has the advantages of fewer complications and less trauma than conventional axillary lymph node dissection (ALND). Common mapping methods for SLNB include blue dye, radioisotopes, a combination of blue dye and radioisotopes, and fluorescence imaging. To standardize the SLNB techniques for breast cancer, the Chinese Society of Breast Surgery (CSBrS) re-evaluated the quality of evidence for clinical studies of SLNB for breast cancer, referring to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), and developed the Clinical Practice Guidelines for Sentinel Lymph Node Biopsy in Patients with Early-Stage Breast Cancer: CSBrS Practice Guidelines 2021, in accordance with the Expert Consensus and Technical Operational Guidelines for Sentinel LymphNode Biopsy guided by blue dye alone in Early Breast Cancer (2018) combined with data from clinical practice in breast surgery in China, providing a reference for breast surgeons in clinical practice in China.

Keywords

Identifiers

DOI

10.1097/CM9.0000000000001410

Journal

Chinese Medical Journal

Year

2021